Package 50242-933-01

Brand: tecentriq hybreza

Generic: atezolizumab and hyaluronidase-tqjs
NDC Package

Package Facts

Identity

Package NDC 50242-933-01
Digits Only 5024293301
Product NDC 50242-933
Product ID 50242-933_9bc7ee05-8ccb-489b-94a9-eb317f72324e
Description

1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01) / 15 mL in 1 VIAL, SINGLE-DOSE

Marketing

Marketing Status
Marketed Since 2024-09-12
Brand tecentriq hybreza
Generic atezolizumab and hyaluronidase-tqjs
Sample Package No

Linked Drug Pages (1)

Tecentriq Hybreza ndc-match (0.95)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["SUBCUTANEOUS"], "spl_id": "9bc7ee05-8ccb-489b-94a9-eb317f72324e", "openfda": {"nui": ["N0000191260", "N0000191259", "M0556300", "M0001357", "M0001352", "N0000175531", "M0009499"], "unii": ["52CMI0WC3Y", "743QUY4VD8"], "rxcui": ["2693892", "2693899"], "spl_set_id": ["a617b089-ce66-464b-987b-b45d029b4d6f"], "pharm_class_cs": ["Antibodies, Monoclonal, Humanized [CS]", "Antibodies, Monoclonal [CS]", "Antibodies [CS]", "Glycoside Hydrolases [CS]"], "pharm_class_epc": ["Programmed Death Receptor-1 Blocking Antibody [EPC]", "Endoglycosidase [EPC]"], "pharm_class_moa": ["Programmed Death Receptor-1-directed Antibody Interactions [MoA]"], "manufacturer_name": ["Genentech, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01)  / 15 mL in 1 VIAL, SINGLE-DOSE", "package_ndc": "50242-933-01", "marketing_start_date": "20240912"}, {"sample": true, "description": "1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86)  / 15 mL in 1 VIAL, SINGLE-DOSE", "package_ndc": "50242-933-86", "marketing_start_date": "20240912"}], "brand_name": "Tecentriq Hybreza", "product_id": "50242-933_9bc7ee05-8ccb-489b-94a9-eb317f72324e", "dosage_form": "INJECTION", "pharm_class": ["Antibodies [CS]", "Antibodies", "Monoclonal [CS]", "Antibodies", "Monoclonal", "Humanized [CS]", "Endoglycosidase [EPC]", "Glycoside Hydrolases [CS]", "Programmed Death Receptor-1 Blocking Antibody [EPC]", "Programmed Death Receptor-1-directed Antibody Interactions [MoA]"], "product_ndc": "50242-933", "generic_name": "atezolizumab and hyaluronidase-tqjs", "labeler_name": "Genentech, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Tecentriq Hybreza", "active_ingredients": [{"name": "ATEZOLIZUMAB", "strength": "1875 mg/15mL"}, {"name": "HYALURONIDASE (HUMAN RECOMBINANT)", "strength": "30000 U/15mL"}], "application_number": "BLA761347", "marketing_category": "BLA", "marketing_start_date": "20240912", "listing_expiration_date": "20261231"}